menu
    • menu
    [{"orgOrder":0,"company":"Paradigm Therapeutics","sponsor":"Eshelman Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Glyoxyldiureide","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Paradigm Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Cream","sponsorNew":"Paradigm Therapeutics \/ Eshelman Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Therapeutics \/ Eshelman Ventures"},{"orgOrder":0,"company":"Paradigm Therapeutics","sponsor":"Eshelman Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Glyoxyldiureide","moa":"Undisclosed||Undisclosed||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Paradigm Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Cream","sponsorNew":"Paradigm Therapeutics \/ Eshelman Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Therapeutics \/ Eshelman Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals for 05670_FLUKA

    Menu

    05670_FLUKA

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Paradigm Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Paradigm Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glyoxyldiureide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Eshelman Ventures

                            Deal Size : $25.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Paradigm Announces an Additional Investment by Eshelman Ventures, LLC

                            Details : The financing aims to advance the late-stage program Zorblisa (allantoin), which is being evaluated for the treatment of Epidermolysis Bullosa.

                            Product Name : Zorblisa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 18, 2025

                            Lead Product(s) : Glyoxyldiureide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Eshelman Ventures

                            Deal Size : $25.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Paradigm Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Paradigm Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glyoxyldiureide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Eshelman Ventures

                            Deal Size : $12.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Paradigm Therapeutics gets Eshelman Funding for SD-101 Topical EB Treatment

                            Details : The financing aims to advance the late-stage program Zorblisa (allantoin), which is being evaluated for the treatment of Epidermolysis Bullosa.

                            Product Name : Zorblisa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : Glyoxyldiureide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Eshelman Ventures

                            Deal Size : $12.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth